Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor...

Area of Science:

• Immunology
• Biotechnology
• Cancer Therapy

Background:

• Chimeric antigen receptor (CAR) T cells are a promising cancer therapy, but their expansion relies on specific tumor-associated antigens (TAAs).
• Current methods require artificial antigen-presenting cells (aAPC) engineered for each TAA, limiting the application of CAR T cells with multiple specificities.
• This limitation hinders the development and clinical translation of CAR T cell therapies targeting diverse cancers.

Purpose of the Study:

• To develop a universal method for expanding CAR T cells of various specificities.
• To overcome the limitations of TAA-specific aAPC in CAR T cell expansion.
• To simplify the manufacturing process and reduce the cost of CAR T cell therapies.

Main Methods:

• Engineered artificial antigen-presenting cells (aAPC) to express a CAR ligand (CARL) that binds the conserved IgG4 extracellular domain of CAR.
• Utilized CARL-expressing aAPC for the ex vivo numeric expansion of CAR T cells.
• Demonstrated the ability of CARL aAPC to propagate CAR T cells with multiple specificities.

Main Results:

• CARL aAPC successfully expanded CAR T cells irrespective of their TAA specificity.
• This approach enables the expansion of CAR T cells targeting multiple specificities using a single aAPC platform.
• CARL eliminates the need for TAA-specific aAPC, reducing technical challenges and costs.

Conclusions:

• CARL represents a significant advancement in CAR T cell expansion technology.
• This universal expansion method simplifies the manufacturing, testing, and clinical translation of diverse CAR T cell therapies.
• CARL has the potential to accelerate the development and accessibility of CAR T cell-based cancer treatments.